More than 50 percent of all menopausal women experience hot flashes, which
can persist for an average of seven years. While effective and safe when
used appropriately, hormone therapy involves some risk and not all patients
are appropriate candidates or ready to try this treatment option.
Fortunately, a new group of non-hormonal drugs, called NK3R
antagonists, have emerged as a viable alternative to hormone therapy. These
drugs disrupt a signaling pathway in the brain that has been linked to the
development of hot flashes and have shown promise in clinical trials for
relieving moderate to severe menopausal hot flashes as effectively as
hormones.
While additional studies are needed to fully understand the
effectiveness and safety of these new drugs, it is clear that the next
generation of non-hormonal treatments for menopausal hot flashes.
can persist for an average of seven years. While effective and safe when
used appropriately, hormone therapy involves some risk and not all patients
are appropriate candidates or ready to try this treatment option.
Fortunately, a new group of non-hormonal drugs, called NK3R
antagonists, have emerged as a viable alternative to hormone therapy. These
drugs disrupt a signaling pathway in the brain that has been linked to the
development of hot flashes and have shown promise in clinical trials for
relieving moderate to severe menopausal hot flashes as effectively as
hormones.
While additional studies are needed to fully understand the
effectiveness and safety of these new drugs, it is clear that the next
generation of non-hormonal treatments for menopausal hot flashes.
